ClinicalTrials.gg
TerminatedNCT03297398Updated Sep 16, 2021Results posted

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

A Phase 2 interventional study of Group-1 (15mg, OPK-88004) and Group-2 (25 mg,OPK-88004) in Benign Prostatic Hyperplasia, sponsored by OPKO Health, Inc.. Terminated at 15 sites in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
study terminated by sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
66th of 150
114 · median 83
Started
2018
with 6 others
Phase 2
27 of 187
3 open now
Registered
110th of 187
by date

Among the 187 studies in Prostatic Hyperplasia with a site in United States, this one is the 66th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2018, is one of 27 in phase 2, and was the 110th registered.

Prostatic Hyperplasia

830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 187 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).

Read the detailed description

Study SAR-202 is a phase 2 multicenter, placebo-controlled, double-blind trial to evaluate the effect of OPK-88004 doses (OPK-88004 15 mg, or OPK-88004 25 mg) on serum PSA compared to placebo in men with BPH. Approximately 115 men with BPH will be enrolled in the study, randomized 1:1:1 across three arms (placebo, OPK-88004 15 mg, or OPK-88004 25 mg). The trial will be conducted at approximately up to 35 sites within the US.

The study duration for individual subjects will be up to 24 weeks and will include three phases:

  • a screening period (up to 4 weeks, including 1-week washout if required),
  • a treatment period (16 weeks), and
  • a follow-up period (4 weeks) Subjects will be randomized and receive their first dose of study drug at visit 2. They will begin the once daily oral dosing regimen and return every 4 weeks to the study site during the 16-week treatment period. Assessments during the study period will include vital signs, laboratory testing, weight, adverse events (AEs), concomitant drugs, and study drug compliance. Efficacy assessments will include serum PSA, LBM and fat mass by DXA scans, uroflowmetry parameters, PVR (by ultrasound), and assessment of symptoms by IPSS.
03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible if they meet the following criteria:

  1. Present with BPH-LUTS based on disease diagnostic criteria at visit 1
  2. Are men aged 45 years or older at visit 1
  3. Have prostate volume >40 cm3 and \<80 cm3 assessed by TRUS at visit 1
  4. Have a PSA >1.5 and \<10.0 ng/mL at visit 1. This PSA blood draw must be performed at least 1 week after any digital rectal exam (DRE) and/or transrectal ultrasound (TRUS) procedures
  5. Subjects with a PSA ≥4.0 and \<10.0 ng/mL must have documentation of a negative histologic of carcinoma of the prostate within 12 months of screening (visit 1). For subjects aged ≤80 years and who have not undergone any invasive urological procedure within 6 months, if biopsy has not been performed, then 4Kscore Test value must be \<7.5% at visit 1
  6. Have laboratory tests within normal limits (with the exception of total serum or free testosterone). If laboratory test results are outside normal limits they are determined to be not at visit 1
  7. Have not received prior treatment with 5-ARIs (finasteride, dutasteride) within the past one year for any indication
  8. Have not received herbal BPH preparations within 1 week of visit 1. If the subject is currently on such treatment, a 1-week will be required
  9. Agree not to use 5-ARIs, herbal or experimental treatments for BPH, at any time during the study. Subjects on daily PDE5i's, alpha-blockers or anticholinergic medications for BPH should remain on a stable dose during the study, unless a change in dose is medically warranted. Occasional-use PDE5i's for ED are permitted at a stable dose and frequency, however should not be taken within 72 hours prior to a study visit
  10. Agree to use an acceptable method of during the study and for 60 days after the last dose of IP, unless the female partner is . Postmenopausal is defined as a female >50 years of age and 12 months of amenorrhea, or surgically postmenopausal
  11. Are reliable and willing to make themselves available for the duration of the study, and who will comply with the required study and dosing visits and abide by the Clinical Research Site policy and procedure and study restrictions
  12. Have given written

Exclusion criteria

Exclusion Criteria

Patients will be excluded from study enrollment if they meet any of the following criteria at visit 1:

  1. History of any of the following pelvic conditions:

    • radical prostatectomy, pelvic surgery for removal of , or bowel resection
    • pelvic radiotherapy
    • any pelvic surgical procedure on the urinary tract, including transurethral resection of the prostate (TURP), penile implant surgery
    • lower urinary tract malignancy or trauma
    • pelvic surgery or any other pelvic procedure less than 6 months prior to visit 1
  2. Lower urinary tract instrumentation (including prostate ) within 6 weeks prior to screening PSA blood draw
  3. History of urinary retention or lower urinary tract (bladder) stones within 1 month of visit 1
  4. Minimally invasive procedures for BPH, such as prostatic stent, high intensity focused ultrasound (HIFU), holmium laser enucleation of prostate (HoLEP), interstitial laser coagulation (ILC), transurethral electroevaporation of the prostate (TUVP), transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), photoselective vaporization (PVP), UroLift, within 6 weeks
  5. Clinical evidence of urinary tract infection or urinary tract inflammation (including prostatitis)
  6. Intravesical obstruction (eg, intravesical median lobe of the prostate)
  7. Current neurologic disease or condition associated with neurogenic bladder (eg, Parkinson's disease, multiple sclerosis)
  8. History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated \<45 mL/min
  9. Active hepatobiliary disease or serologic evidence of active hepatitis A, B, C, hepatitis E or
  10. (AST) or alanine aminotransferase (ALT) greater than 2X the (ULN)
  11. Glycosylated () >9%
  12. Hematocrit ≥50%
  13. HDL-C \<35 mg/dL and LDL-C >130 mg/dL
  14. interval >450 msec. For heart rates over 75, the may be repeated after 5 minutes of resting quietly
  15. Abnormality in ECG (eg, left bundle branch block, complete right bundle branch block, or delayed intraventricular conduction with a QRS interval >120 msec) that in the opinion of the investigator places the subject at an unacceptable risk for study participation, or subject has implanted pacemaker
  16. History of any of the following cardiac/coronary conditions within 90 days:

    • history of myocardial infarction or coronary artery bypass graft
    • percutaneous coronary intervention
    • stroke
  17. Any evidence of heart disease ( ≥Class II, Appendix 4) within 6 months, or are receiving treatment for congestive heart failure (CHF)
  18. Any supraventricular or ventricular arrhythmia with uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical therapy
  19. Systolic blood pressure >160 or \<90 mm Hg or diastolic blood pressure >100 or \<50 mm Hg as determined by a sitting measurement (if stress is suspected, retest up to two times under basal conditions), or malignant hypertension
  20. Have a history or presence of prostatic carcinoma, as well as any conditions that may be exacerbated by androgenic medications such as (but not limited to) epilepsy, seizures, convulsions, migraine or polycythemia
  21. History of cancer within the previous 5 years, except for excised superficial lesions (such as basal cell carcinoma and squamous cell carcinoma of the skin)
  22. History of drug, alcohol, or substance abuse within 6 months
  23. Have an alcohol intake of ≥3 units/day or ≥14 units/week during the study (1 unit = 12 ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits)
  24. Any condition that would interfere with subject's ability to provide or comply with study instructions, would impair ability to perform the study assessments, or would place subject at increased risk, or might confound the interpretation of the study results
  25. Current treatment with androgens, antiandrogens, estrogens, or anabolic steroids within the prior 1 month. Any prior or current treatment with LHRH agonists/antagonists
  26. Current treatment with potent inhibitors such as itraconazole or ritonavir
  27. Have taken prescription or over-the-counter medications to promote weight loss within the prior 3 months
  28. Any prior use of OPK-88004 Allergic to any component of OPK-88004
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Placebo comparator
    Other

    Placebo Group

    Other: Placebo

  • Experimental
    Drug Group 1

    15mg, OPK-88004

    Drug: Group-1 (15mg, OPK-88004)

  • Experimental
    Drug Group 2

    25,mg OPK-88004

    Drug: Group-2 (25 mg,OPK-88004)

Interventions

  • DrugGroup-1 (15mg, OPK-88004)

    15mg, OPK-88004

    Also known as: Selective Androgen Receptor Modulator

  • DrugGroup-2 (25 mg,OPK-88004)

    25 mg,OPK-88004

    Also known as: Selective Androgen Receptor Modulator

  • OtherPlacebo

    Placebo

    Also known as: Inactive

06

What researchers measure

Primary outcomes

  1. Change From Baseline in PSA (%) to Week 16

    The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo

    Time frame: 16 weeks

Secondary outcomes

  1. Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks

    To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass

    Time frame: 16 weeks

Other outcomes

  1. To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)

    Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

    Time frame: 16 weeks

  2. To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)

    Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

    Time frame: 16 weeks

  3. To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)

    Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

    Time frame: 16 weeks

  4. To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)

    Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

    Time frame: 16 weeks

  5. International Prostate Symptom Score- IPSS

    To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)

    Time frame: 16 weeks

07

Results

Posted Jul 28, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboOPK-88004 15 mgOPK-88004 25 mg
Started364038
Completed282323
Not completed81715
Withdrew: Sponsor's decision697
Withdrew: Adverse event144
Withdrew: Withdrawal by subject122
Withdrew: Protocol violation020
Withdrew: Physician decision001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange From Baseline in PSA (%) to Week 16

The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo

Time frame:
16 weeks
Reported as:
Least squares mean · Percentage of serum PSA change
Change From Baseline in PSA (%) to Week 16
Percentage of serum PSA changeOtherDrug Group 1Drug Group 2
Change From Baseline in PSA (%) to Week 16-2.96 ± 5.198-1.48 ± 5.569-15.44 ± 5.509
SecondaryAbsolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks

To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass

Time frame:
16 weeks
Reported as:
Least squares mean · gram
Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks
gramOtherDrug Group 1Drug Group 2
Change from Baseline in Lean Body Mass (g) to Week 1637.8 ± 439.621610.3 ± 489.451961.6 ± 522.58
Change from Baseline in Fat Mass (g) to Week 16-198.2 ± 326.84-1468.7 ± 373.06-1491.3 ± 388.98
Other pre-specifiedTo Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)

Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

Time frame:
16 weeks
Reported as:
Least squares mean · millilitre/second
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)
millilitre/secondOtherDrug Group 1Drug Group 2
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)4.26 ± 3.8100.61 ± 4.0721.08 ± 4.043
Other pre-specifiedTo Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)

Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

Time frame:
16 weeks
Reported as:
Least squares mean · millilitre/second
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)
millilitre/secondOtherDrug Group 1Drug Group 2
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)-0.40 ± 0.475-0.30 ± 0.5090.15 ± 0.505
Other pre-specifiedTo Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)

Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

Time frame:
16 weeks
Reported as:
Least squares mean · millilitre
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)
millilitreOtherDrug Group 1Drug Group 2
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)-49.12 ± 21.294-2.28 ± 22.501-29.12 ± 22.714
Other pre-specifiedTo Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)

Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16

Time frame:
16 weeks
Reported as:
Least squares mean · millilitre
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)
millilitreOtherDrug Group 1Drug Group 2
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)-0.08 ± 10.36517.63 ± 11.325-15.19 ± 10.925
Other pre-specifiedInternational Prostate Symptom Score- IPSS

To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)

Time frame:
16 weeks
Reported as:
Mean · Total IPSS score
International Prostate Symptom Score- IPSS
Total IPSS scoreOtherDrug Group 1Drug Group 2
International Prostate Symptom Score- IPSS14.0 ± 7.7012.8 ± 6.2114.2 ± 7.28

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Other0/36 (0%)0/36 (0%)5/36 (13.9%)
Drug Group 10/40 (0%)0/40 (0%)25/40 (62.5%)
Drug Group 20/38 (0%)2/38 (5.3%)30/38 (78.9%)
Most frequent serious events
Most frequent serious events
EventOtherDrug Group 1Drug Group 2
Coronary artery diseaseCardiac disorders0/360/401/38
Bile duct obstructionHepatobiliary disorders0/360/401/38
CholangitisHepatobiliary disorders0/360/401/38
Most frequent other events
Showing 10 of 23
Most frequent other events
EventOtherDrug Group 1Drug Group 2
Blood testosterone decreasedInvestigations0/367/405/38
High density lipoprotein decreasedInvestigations0/361/404/38
Upper respiratory tract infectionInfections and infestations0/362/403/38
Low density lipoprotein increasedInvestigations0/363/403/38
Transaminases increasedInvestigations1/362/403/38
Blood testosterone free decreasedInvestigations0/361/403/38
Sperm concentration decreasedInvestigations0/361/403/38
Prostatic specific antigen increasedInvestigations0/363/402/38
Alanine aminotransferase increasedInvestigations0/363/401/38
Aspartate aminotransferase increasedInvestigations0/363/401/38

Baseline characteristics

Age, Continuous
Age, Continuous(Year)OtherDrug Group 1Drug Group 2Total
Mean64.1 ± 6.5264.5 ± 5.7765.3 ± 6.0164.6 ± 6.06
Sex: Female, Male
Sex: Female, Male(Participants)OtherDrug Group 1Drug Group 2Total
Female0000
Male364038114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OtherDrug Group 1Drug Group 2Total
Hispanic or Latino73515
Not Hispanic or Latino29373399
Unknown or Not Reported0000
Weight (kilogram)
Weight (kilogram)(Kilogram)OtherDrug Group 1Drug Group 2Total
Mean94.97 ± 16.93795.31 ± 19.12891.35 ± 13.56493.88 ± 16.692
Body mass index (kilogram/meter^2)
Body mass index (kilogram/meter^2)(Kilogram/meter^2)OtherDrug Group 1Drug Group 2Total
Mean30.17 ± 5.11430.37 ± 5.28629.36 ± 3.44229.97 ± 4.671
08

Study locations

15 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Bayview Research Group, LLC - Valley Village
    Valley Village, California 91607, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • APF Research, LLC
    Miami, Florida 33134, United States
  • Meridien Research - Brooksville
    Spring Hill, Florida 34609, United States
  • Florida Urology Partners
    Tampa, Florida 33615, United States
  • Advanced Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Regional Urology
    Shreveport, Louisiana 71106, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • AccuMed Research Associates
    Garden City, New York 11530, United States
  • Manhattan Medical Research Practice PLLC
    New York, New York 10016, United States
  • Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville
    Knoxville, Tennessee 37920, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2019, 13 months.

Results were first posted in Jul 2021, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Sep 29, 2017
StartActual
Feb 21, 2018
Primary completionActual
Apr 18, 2019
CompletionActual
Jun 10, 2019
Results first posted
Jul 28, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03297398
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
Feb 21, 2018
Primary completion
Apr 18, 2019
Completion
Jun 10, 2019
Results posted
Jul 28, 2021
Last update
Sep 16, 2021

Study contacts

Militza Vera De Alba, MD
study director · Dr.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion